Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 1
1968 1
1975 2
1976 2
1978 2
1980 1
1981 1
1982 1
1985 2
1986 1
1987 1
1988 1
1989 2
1990 4
1991 5
1992 8
1993 13
1994 16
1995 25
1996 44
1997 70
1998 73
1999 84
2000 102
2001 131
2002 153
2003 175
2004 215
2005 203
2006 228
2007 260
2008 260
2009 271
2010 293
2011 323
2012 348
2013 302
2014 366
2015 343
2016 303
2017 286
2018 294
2019 291
2020 326
2021 316
2022 266
2023 266
2024 111

Text availability

Article attribute

Article type

Publication date

Search Results

6,041 results

Results by year

Filters applied: . Clear all
Page 1
CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment.
Silvado CE, Terra VC, Twardowschy CA. Silvado CE, et al. Pharmgenomics Pers Med. 2018 Mar 29;11:51-58. doi: 10.2147/PGPM.S108113. eCollection 2018. Pharmgenomics Pers Med. 2018. PMID: 29636628 Free PMC article. Review.
The metabolization of PHT is carried out by two oxidative cytochrome P450 enzymes CYP2C9 and CYP2C19; 90% of this metabolization is done by CYP2C9 and the remaining 10% by CYP2C19. ...In patients with CYP2C9 *1/*2 or *1/*3 alleles (intermediate metabolizers), …
The metabolization of PHT is carried out by two oxidative cytochrome P450 enzymes CYP2C9 and CYP2C19; 90% of this metabolization is d …
Relevance of CYP2C9 Function in Valproate Therapy.
Monostory K, Nagy A, Tóth K, Bűdi T, Kiss Á, Déri M, Csukly G. Monostory K, et al. Curr Neuropharmacol. 2019;17(1):99-106. doi: 10.2174/1570159X15666171109143654. Curr Neuropharmacol. 2019. PMID: 29119932 Free PMC article. Review.
RESULTS: The loss-of-function alleles, CYP2C9*2 or CYP2C9*3, display significant reduction in valproate metabolism in children; furthermore, low CYP2C9 expression in patients with CYP2C9*1/*1 genotype also leads to a decrease in valproate metabolizing …
RESULTS: The loss-of-function alleles, CYP2C9*2 or CYP2C9*3, display significant reduction in valproate metabolism in children …
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
Daly AK, Rettie AE, Fowler DM, Miners JO. Daly AK, et al. J Pers Med. 2017 Dec 28;8(1):1. doi: 10.3390/jpm8010001. J Pers Med. 2017. PMID: 29283396 Free PMC article. Review.
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most important contributor from this subfamily to drug metabolism. ...CYP2C9 substrate selectivity is detailed and, based on crystal structures for the enzyme, we describe how CYP2C9 ca …
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most important contributor from this subfamily to drug meta …
CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Franco V, Perucca E. Franco V, et al. Expert Opin Drug Metab Toxicol. 2015;11(8):1269-79. doi: 10.1517/17425255.2015.1053463. Epub 2015 Jun 3. Expert Opin Drug Metab Toxicol. 2015. PMID: 26037375 Review.
AREAS COVERED: Comprehensive and critical review of available evidence concerning the influence of CYP2C9 genetic polymorphism on phenytoin pharmacokinetic and safety profile. ...The clinical value and cost-effectiveness of CYP2C9 genotyping in improving the safety …
AREAS COVERED: Comprehensive and critical review of available evidence concerning the influence of CYP2C9 genetic polymorphism on phe …
Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions.
Wang K, Gao Q, Zhang T, Rao J, Ding L, Qiu F. Wang K, et al. Drug Metab Rev. 2020 May;52(2):235-257. doi: 10.1080/03602532.2020.1758714. Epub 2020 May 14. Drug Metab Rev. 2020. PMID: 32406758 Review.
Diclofenac (4'-hydroxylase) and tolbutamide (methylhydroxylation) are widely used as probe substrates for CYP2C9. To date, numerous natural products have been reported to have the capabilities of inhibiting the catalytic activity of CYP2C9 and further influencing th …
Diclofenac (4'-hydroxylase) and tolbutamide (methylhydroxylation) are widely used as probe substrates for CYP2C9. To date, numerous n …
Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia.
Mosikian A, Dolgorukova A, Zalevskaya A. Mosikian A, et al. Pharmacogenomics. 2016 Dec;17(18):2115-2126. doi: 10.2217/pgs-2016-0121. Epub 2016 Nov 25. Pharmacogenomics. 2016. PMID: 27885968 Review.
AIM: To evaluate a possible role of CYP2C9 genotyping for sulfonylureas (SUs) prescription in Russia. MATERIALS & METHODS: We have collected the current data on correlation between SUs pharmacodynamics and CYP2C9 polymorphisms. We have evaluated the frequency of …
AIM: To evaluate a possible role of CYP2C9 genotyping for sulfonylureas (SUs) prescription in Russia. MATERIALS & METHODS: We hav …
CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations.
Nizamuddin S, Dubey S, Singh S, Sharma S, Machha P, Thangaraj K. Nizamuddin S, et al. Pharmgenomics Pers Med. 2021 Jan 27;14:135-147. doi: 10.2147/PGPM.S272015. eCollection 2021. Pharmgenomics Pers Med. 2021. PMID: 33536773 Free PMC article.
As South Asians have high frequency, it would be interesting to explore potential of CYP2C9*3 as a marker for personalized therapy. Our study revealed several rare functional variants, which form eight novel and rare haplotypes of CYP2C9 (CYP2C9*63-*70). ...C …
As South Asians have high frequency, it would be interesting to explore potential of CYP2C9*3 as a marker for personalized therapy. O …
Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis.
Wu X, Liu W, Zhou W. Wu X, et al. J Clin Pharm Ther. 2018 Jun;43(3):408-413. doi: 10.1111/jcpt.12660. Epub 2017 Dec 23. J Clin Pharm Ther. 2018. PMID: 29274302 Review.
WHAT IS KNOWN AND OBJECTIVE: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions that can be induced by phenytoin (PHT). CYP2C9*3 is the key enzyme in PHT metabolism. The aim of this meta-analysis was to evaluate the a …
WHAT IS KNOWN AND OBJECTIVE: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions that …
VKORC1 and CYP2C9 genotype distribution in Asian countries.
Gaikwad T, Ghosh K, Shetty S. Gaikwad T, et al. Thromb Res. 2014 Sep;134(3):537-44. doi: 10.1016/j.thromres.2014.05.028. Epub 2014 May 27. Thromb Res. 2014. PMID: 24908449 Review.
METHOD: A systematic electronic search was carried out in PUBMED and ScienceDirect using different key words like, 'warfarin', 'CYP2C9', 'VKORC1', 'pharmacokinetics', 'metabolites' and 'genetic'. Till date, data from 15 Asian countries for CYP2C9 genotypes and 14 As …
METHOD: A systematic electronic search was carried out in PUBMED and ScienceDirect using different key words like, 'warfarin', 'CYP2C9 …
Functional characterization of the defective CYP2C9 variant CYP2C9*18.
Liu J, Chen H, Wang SH, Zhou Q, Geng PW, Zhou YF, Wu HL, Shi HF, Wang F, Yang JF, Cai JP, Dai DP. Liu J, et al. Pharmacol Res Perspect. 2021 Feb;9(1):e00718. doi: 10.1002/prp2.718. Pharmacol Res Perspect. 2021. PMID: 33508175 Free PMC article.
CYP2C9*18 is one CYP2C9 allelic variant identified in a Southeast Asian population and is estimated to cause the amino acid substitutions of I359L and D397A in CYP2C9 enzyme simultaneously. ...As compared with that of wild-type enzyme, both CYP2C9.18 v …
CYP2C9*18 is one CYP2C9 allelic variant identified in a Southeast Asian population and is estimated to cause the amino acid su …
6,041 results